GovChime
Notice ID: 4a41a91156584f8d9faac3d1967377b6Combined Synopsis/Solicitation

Infinium CoreExome array/research SNP array

Archived on October 5, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM UTC−06:00
Posted
September 10, 2020
Notice type
Combined Synopsis/Solicitation
NAICS
541380: Testing Laboratories and Services
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Bethesda, MD, 20814
Last updated
Apr 29, 2026

Identifiers

Solicitation number
RFQ-RML-C-2034174
Notice ID
4a41a91156584f8d9faac3d1967377b6

Description

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 Streamlined Procedures for Evaluation and solicitation for commercial Items, as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-RML-C-2034174 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2020-07 August 31, 2020. The North American Industry Classification System (NAICS) code for this procurement is 541380, Testing Laboratories, with a small business size standard of $15 million. The requirement is being competed full and open competition, un-restricted and without a small business set-aside. The National Institute of Allergy and Infectious Diseases (NIAID) has a requirement for: Infinium CoreExome array/research SNP array QTY: 350 WORK INCLUDES: 1) BACKGROUND INFORMATION The National Institute of Allergy and Infectious Disease (NIAID) Division of Intramural Research (DIR) scientists study all aspects of infectious diseases, including the causative agent, vectors, and pathogenesis in human and animal hosts. Clinical research is an integral part of this mission, enabling key lab discoveries to be rapidly translated into methods to prevent, diagnose, or treat disease. DIR researchers annually conduct more than 200 clinical trials at the NIH Clinical Center on the Bethesda, Maryland, campus and at collaborating U.S. and international sites. In support of clinical research, the NIAID Centralized Sequencing Initiative is comprehensive program that obtains genetic testing, harmonizes phenotypic and genomic data, performs variant interpretation, and provides clinically-validated results for patients enrolled in a diverse set of protocols at the NIH Clinical Center. The goal of the NIAID Centralized Sequencing Initiative is both to contribute to the understanding of underlying genetic etiology of disease and to address the clinical need for genomic evaluations. 2) PURPOSE AND OBJECTIVES OF THE ACQUISITION The purpose of this acquisition is to support the mission DIR to obtain genetic testing for the NIAID Centralized Sequencing Initiative. The centralized sequencing initiative will have direct implications for the care of NIH patients and for the discovery of disease mechanisms. The types of sequencing required for the initiative are; custom microarrays for Comparative Genomic Hybridization (CGH), SNP microarrays, whole Genome Sequencing (WGS) and RNAseq. Genome sequencing allows for discovery of monogenic and polygenic contributions to disease. Clinical microarrays will provide clinical analysis of copy number variants contributing to those diseases. This particular acquisition focuses on research genome-wide SNP arrays to enable the study of common variants. 3) CONTRACTOR REQUIREMENTS: Research SNP array with genome-wide coverage of common variants (N = 350) o Sample processing and microarray scanning o Feature extraction: processing of raw image files o QC of data including sample identity analysis, assessment of contamination, sex, and relationships with other samples o Delivery of batch-specific and cumulative PLINK binary files and raw data files, e.g. GenomeStudio files 4) CONTRACTOR SUPPLIED MATERIALS The Contractor shall provide plates for shipping and all consumable reagents except those mentioned below. 5) GOVERNMENT FURNISHED MATERIALS NIAID will supply patient samples. If genomic DNA samples are used, NIAID will deliver them in 96-well plates with tubes containing 2D barcodes. Exclusionary criteria: NIAID will not be able to affix labels to individual tubes. 6) REPORTING REQUIREMENTS AND DELIVERABLES Deliverable format: Delivery of batch-specific and cumulative PLINK binary files and raw data files, e.g. GenomeStudio files within 6 weeks. Inclusion of QC metrics for data including sample identity analysis, assessment of contamination, sex, and relationships with other samples. Transfer to occur via cloud-based platform that meets security requirements for transfer to NIH/NIAID servers. 7) INSPECTION AND ACCEPTANCE All deliverables will be inspected by the project manager, an employee of the Division of Intramural Research. Acceptance will occur when results are successfully transferred to NIH per the specifications and format outline in the requirements above. Place of Performance: NIH, Clinical Center, BUILDING 10 Bethesda, MD 20852, United States. FOB DESTINATION The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following; technical capability to meet the requirements and price. The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (June 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (AUG 2020) FAR 52.204-7 System for Award Management (Oct 2018) (Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements Representation (Jan 2017) 52.204 24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (AUG 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-24 AND returned with quote. (NO EXCEPTIONS) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (AUG 2020) FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (AUG 2020) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-13 System for Award Management Maintenance (Oct 2018) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 2015) 52.252-2 -- Clauses Incorporated by Reference. (Feb 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Submission shall be received not later than September 20, 2020 @ 9:00 AM MST Offers may be e-mailed to Diana Rohlman (E-Mail/ diana.rohlman@nih.gov). Offers shall include RFQ number in the subject line (RFQ-RML-C-2034174). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Diana Rohlman, diana.rohlman@nih.gov.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:RFQ-RML-C-2034174
  1. Combined Synopsis
  1. Combined SynopsisCurrentSep 10, 2020

    Infinium CoreExome array/research SNP array

    Notice 4a41a91156584f8d9faac3d1967377b6 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Small Businesses interested and capable of providing the services described below. NIH-OD-SS-27-000058 The information gained from this market research will help the National Institutes (NIH) Clinical Center (CC) plan for its acquisition strategy. Potential Large and Small Businesses shall include business information outlined in the section below as a part of their response. Complete responses to this notice shall be in the following format: SAM UEI Number and CAGE code Company Name Company Address, City, State and Zip Code Company Point of Contact, Email Address and Telephone Number Current GSA Schedule appropriate to this Sources Sought of other FAR Part 8 considerations Socioeconomic Status: (i.e., HUBZone, 8a, Small Business, Women Owned Small Business, Veteran-Owned Small-Business, etc.) https://www.sam.gov. Provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described in the Statement of Work. The NIH Clinical Center Office of Research Support and Compliance (ORSC) is seeking a qualified and experienced contractor to provide project management and coordination of routine and emergent qualification, calibration/PM and certification services, including repairs and replacements, for the departments/ICs located at the NIH’s Bethesda, MD campus. Please see attached SOW for more details. Contractors shall not reach out to the customer for any questions or clarifications. All communications must go through contracting. ****************************************************************************** Important information: The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. NAICS: The North American Classification System (NAICS) code for this acquisition is 541380. PSC: H966 Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered and have an active registration in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). All interested Offerors should submit information by e-mail to ryssa.nix@nih.gov. Please use subject line “Response to NIH-OD-SS-27-000058”. All information submissions shall be received no later than noon on November 15, 2026.
-Pre-Solicitation11/15/2026
INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Alcami Corporation 2320 Scientific Park DR Wilmington, North Carolina 28405-1800 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541380 with a Size Standard $16.6M. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Background Information: NHGRI was gifted 48kg of unlabeled drug ManNAc (powder-in-sachet) in September 2025, and agreed to take over the FDA-required, mandatory, stability testing program of this drug that has been ongoing at Alcami Corporation since June 2024. The gifted drug was produced in 2 campaigns, Campaign 5 (C5, June 2024) and Campaign 6 (C6, September 2024). NHGRI plans to use the donated clinical grade drug for upcoming clinical trials. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by November 9, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98027Q00040. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.”
-Pre-Solicitation11/09/2026
Centers for Disease Control (CDC) is issuing this synopsis as a means of conducting market research to identify parties having an interest in and the resources to support this requirement for a California-based integrated health care system to serve as an electronic health record site in CDC’s VISION 2.0 respiratory pathogen surveillance network, providing integrated, longitudinal medical, laboratory, pharmacy, vaccination, claims, and outcomes data to support influenza surveillance, vaccine-effectiveness studies, and related respiratory pathogen research across emergency/urgent care, inpatient, and intensive care unit (ICU) settings. The result of this market research will contribute to determining the method of acquisition. The applicable North American Industry Classification System (NAICS) code assigned to this acquisition is 541380- Testing Laboratories and Services.
-Market Research12/04/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01209/PCA-NIA-08501. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Epigenetic Clock Development Foundation 1124 W. Carson Street, MRL Bldg., 3rd Floor Torrance, CA 90502 US to provide obtain DNA methylation profiling and epigenetic age analysis for 320 previously extracted murine DNA samples using the Mammal320K methylation array and established Horvath epigenetic clock methodologies.
-Combined Synopsis09/23/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01212/PCA-NIA-08124. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Metabolon Inc. 617 Davis Drive, Suite 100, Morrisville, NC 27560 to assay global metabolomics data and short chain fatty acids (SCFA) via the Metabolon platform from 369 blood samples in the BLSA. These metabolomics data will be used to identify metabolomic signatures of anthropometric aging quantified via a 3D body scanner.
-Combined Synopsis09/23/2026

Additional Details

Solicitation Number

RFQ-RML-C-2034174

Archive Date

Oct 5, 2020

Office Address

BETHESDA, MD, 20892